Photo from Erman Akkus/X
Sep 26, 2024, 09:30
Erman Akkus: Neoadjuvant CRT vs. ChT for initially unresectable locally advanced ‘Colon’ cancer
Erman Akkus posted on X:
“Neoadjuvant CRT vs. ChT for initially unresectable locally advanced ‘Colon’ cancer.
- 45 patients.
- R0 resection: 80% vs. 20%, P < 0.001.
- 3-year PFS: 76% vs. 45% , P = 0.049.
- 3-year OS: 87.6% vs. 75% , P = 0.037.
- No differences in severe AEs.
Study was terminated prematurely because of R0 resection benefit of CRT.”
Source: Erman Akkus/X
Authors: Zi-Tong Zhang, Wei-Wei Xiao, Li-Ren Li, Xiao-Jun Wu, Qiao-Xuan Wang, Hui Chang, Xue Tian, Wu Jiang, Jun-Zhong Lin, Rong-Xin Zhang, Wen-Hua Fan, Zhi-Zhong Pan, Rong Zhang, and Yuan-Hong Gao.
Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 17, 2024, 01:14
Nov 17, 2024, 01:10
Nov 17, 2024, 01:05
Nov 17, 2024, 01:04
Nov 17, 2024, 00:47
Nov 17, 2024, 00:42